Medicus Pharma Ltd (MDCX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Medicus Pharma CMO to lead Antev's Teverelix clinical programme
Medicus Pharma (NASDAQ:MDCX) announced it has put its chief medical officer in charge of UK subsidiary Antev Limited, consolidating leadership of the Teverelix clinical programme ahead of regulatory, late-stage development and partnering work. Dr Faisal Mehmud will become Antev's chief executive on August 30, while retaining his positions as Medicus chief medical officer and co-chairman of the subsidiary.
Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week announced that the US Food and Drug Administration (FDA) has cleared the company's Phase 2b registration-enabling clinical trial for SkinJect in patients with Gorlin syndrome, representing an important regulatory milestone for its lead investigational asset. Speaking with Proactive, CEO Raza Bokhari said the FDA had approved the company's proposed study following discussions and feedback, allowing Medicus Pharma (NASDAQ:MDCX) to move ahead with a crossover registration study involving up to 50 patients.
Medicus Pharma receives FDA clearance to begin registrational SkinJect study for Gorlin syndrome
Medicus Pharma (NASDAQ:MDCX) said the US Food and Drug Administration (FDA) has issued a "Study May Proceed" letter authorizing the company to begin its NDA-enabling Phase 2b registrational study of SkinJect in patients with Gorlin syndrome who develop multiple basal cell carcinomas. The authorization follows the FDA's review of the company's investigational new drug (IND) application for the SKNJCT-005 study and Medicus' response to information requests issued by the agency in June.
Medicus Pharma Ltd Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 52,643 | $23,490 | $15,792.9 | -$7,697.1 | -32.77% |
 May Hill Capital LLC May Hill Capital LLC | 50,622 | $87,391.15 | $15,166.35 | -$72,224.8 | -82.65% |
Medicus Pharma Ltd (MDCX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Medicus Pharma Ltd ever had a stock split?
Medicus Pharma Ltd Profile
| Biotechnology Industry | Healthcare Sector | Raza Bokhari CEO | NASDAQ (CM) Exchange | 58471K202 CUSIP |
| CA Country | 16 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Medicus Pharma Ltd stands out as a leading entity in the pharmaceutical industry, concentrated on the research, development, and bringing to market innovative health care solutions. The core mission of the firm is to cater to unmet medical needs through the creation of a diversified portfolio of therapeutic treatments, concentrating primarily on areas such as oncology, neurology, and immunology. With a heavy reliance on biotechnology and avant-garde medical research, Medicus Pharma Ltd is firmly positioned as a significant figure in the life sciences domain. The organization is deeply committed to enhancing the quality and efficacy of treatments, thereby contributing significantly to the elevation of global healthcare standards. Beyond its influence on the pharmaceutical landscape, Medicus Pharma Ltd is instrumental in enhancing the health and well-being of patients and healthcare systems worldwide. As a frontrunner in the market, it engages in collaborations with academic bodies and industry counterparts, aiming to stimulate innovation and hasten the delivery of potentially life-saving drugs.
Products and Services
The range of products and services offered by Medicus Pharma Ltd is extensive, with each category tailored to address specific healthcare challenges:
- Oncology Treatments: Medicus Pharma Ltd develops innovative therapies aimed at treating various forms of cancer. These treatments focus on improving patient outcomes and include targeted therapy, immunotherapy, and traditional chemotherapy. By leveraging the latest research in oncology, the company strives to offer more effective and less toxic options to patients.
- Neurology Solutions: In the realm of neurology, the company is dedicated to discovering treatments for neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Through cutting-edge research, Medicus Pharma Ltd aims to provide patients with treatments that can alleviate symptoms, halt disease progression, and improve quality of life.
- Immunology Therapies: Focusing on disorders of the immune system such as autoimmune diseases, Medicus Pharma Ltd is at the forefront of developing therapies that modulate the immune response. These treatments are designed to target underlying causes of immune-related conditions, offering new hope to patients suffering from diseases like rheumatoid arthritis, lupus, and inflammatory bowel disease.
Each product and service provided by Medicus Pharma Ltd encapsulates the company's commitment to pioneering healthcare advancements, ensuring that their offerings not only meet the highest standards of safety and effectiveness but also address the evolving needs of patients and healthcare professionals around the globe.
